【摘要】 胃癌是全球恶性肿瘤之一,绝大多数胃癌患者确诊时已是进展期或晚期,无法进行手术根除。因此对于此类胃癌患者,药物治疗成为主要手段。目前胃癌药物治疗方案可分为化疗、靶向治疗、免疫治疗等,其中阿帕替尼为我国自主研发的一种新型靶向药物,分属于小分子肿瘤血管生成抑制剂,可将血管内皮生长因子(VEGF)及其受体(VEGFR)信号通路作为靶点,特异性的抑制酪氨酸激酶活性,进而抑制肿瘤生长。由于阿帕替尼在治疗胃癌的临床应用中被证实安全有效,2015年阿帕替尼被NCCN临床实践指南列为进展期胃癌二线治疗。近些年,不少学者尝试将阿帕替尼与其他抗肿瘤药物联合应用于进展期及晚期胃癌的治疗中,并且取得了积极的研究成果。因此本文围绕阿帕替尼联合治疗在进展期及晚期胃癌中的研究进展进行综述。更多还原

【Abstract】 Gastric cancer is one of the malignant tumors in the world. The vast majority of patients with gastric cancer are diagnosed in aggressive-phase and advanced stage and can not be eradicated by surgery.Therefore, drug therapy has become the main means for patients with gastric cancer.At present, drug therapy for gastric cancer can be divided into chemotherapy, targeted therapy, immunotherapy and so on. Apatinib is an new targeted drug independently developed in China, which belongs to small molecular tumor angiogenesis inhibitors. Vascular endothelial growth factor(VEGF) and its receptor(VEGFR) signal pathway can be used as targets to specifically inhibit tyrosine kinase activity, and then inhibit tumor growth.As apatinib has been proved to be safe and effective in treatment of gastric cancer, it was listed as the second-line treatment drug of advanced gastric cancer according to NCCN Clinical practice guidelines in 2015.In recent years, many scholars have tried to combine apatinib with the other antineoplastic drugs in treatment of aggressive-phase and advanced gastric cancer, and have achieved positive research results. Therefore, this article reviews the research progress of apatinib combined therapy in treatment of aggressive-phase and advanced gastric cancer.更多还原